-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Untreated constipation is a common non-motor symptom (NMS) in Parkinson's disease (PD)
Constipation may exist in all stages of Parkinson's disease, and may be a particularly disabling NMS in patients with advanced Parkinson's disease
In addition, different studies have found that subjects with chronic constipation have a higher risk of PD, and constipation is considered a prodromal symptom of PD
This link between constipation and Parkinson’s disease risk is thought to be related to the hypothesis of the gut-brain axis in the pathogenesis of Parkinson’s disease.
New evidence suggests that the deposition of a-synuclein may begin in the enteric nervous system and then spread to the brain
New evidence suggests that the deposition of a-synuclein may begin in the enteric nervous system and then spread to the brain
They recruited PD patients and control groups in the COPPADIS cohort from 35 centers in Spain from January 2016 to November 2017
The total score of PD-CRS of patients with constipation decreased significantly (from 89.
In PD patients, constipation at stage V0 is associated with a decrease in the total score of PD-CRS
The important significance of the study lies in the discovery; constipation is related to the cognitive decline of PD patients, but has nothing to do with the control group
Constipation is related to the cognitive decline of PD patients, but has nothing to do with the control group
Leave a message here